All In Biotech

Drug Trial Radar · NCT00385697

The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

A Phase 2/3, Randomized, Double-Blind, Multicenter, Multinational, 4-Arm, Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of MGA031, a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Dec 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 554 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

554

Actual

Start

Oct 2006

Primary completion

Jun 2010

Study completion Aug 2011

Sponsor

Lead sponsor
MacroGenicsIndustry
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Oct 11, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 8 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this protocol is to assess the efficacy, tolerability, and safety of MGA031 when administered according to 3 different MGA031 dosing regimens in children and adults with recent-onset (diagnosis within past 12 weeks) type 1 diabetes mellitus. All regimens will be administered as an addition to insulin and other standard of care treatments. Efficacy will be defined primarily by the capacity of MGA031 to markedly reduce typical insulin requirements while maintaining relatively normal blood sugar levels. Other studies involving the study drug use the name hOKT3γ1 (Ala-Ala). MGA031, a humanized monoclonal antibody, is the name used for hOKT3γ1 (Ala-Ala) that is produced by MacroGenics, Inc. The United States Adopted Name (USAN) for MGA031 is teplizumab.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • TeplizumabBiological

    Daily IV dosing for 14 days, repeated at Week 26

  • PlaceboDrug

    Daily IV dosing for 14 days, repeated at Week 26

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects in Segment 2 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.Time frame: 52 weeks after randomization
  2. Number of Subjects in Segment 1 With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.Time frame: 52 weeks after first dose
  3. Mean HbA1c Change From Baseline in Segment 2Time frame: 52 weeks after randomization
  4. Mean HbA1c Change From Baseline in Segment 1Time frame: 52 weeks after first dose

Locations

115 sites in 16 countries. Site status is shown where the registry gives one.

  • UAB School of Medicine

    Birmingham, Alabama

  • NEA Clinic

    Jonesboro, Arkansas

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Diabetes Medical Center of California

    Northridge, California

  • UCSF Medical Center

    San Francisco, California

  • University of Colorado Health Sciences Center

    Aurora, Colorado

  • Yale University

    New Haven, Connecticut

  • Christiana Care Research Institute

    Newark, Delaware

  • Richard Hays, MD

    Wellington, Florida

  • Atlanta Diabetes Associates

    Atlanta, Georgia

  • Humphrey Diabetes Center

    Boise, Idaho

  • Rocky Mountain Diabetes & Osteoporosis Center

    Idaho Falls, Idaho

  • Riley Hospital for Children

    Indianapolis, Indiana

  • University of Iowa Children's Hospital

    Iowa City, Iowa

  • Mid-America Diabetes Associates, PA

    Wichita, Kansas

  • Commonwealth Biomedical Research, LLC

    Madisonville, Kentucky

  • St. Agnes Hospital

    Baltimore, Maryland

  • Maryland Diabetes & Endocrine Associates

    Rockville, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Baystate Medical Center

    Springfield, Massachusetts

  • Alzohaili Medical Consultants

    Dearborn, Michigan

  • The Children's Mercy Hospital

    Kansas City, Missouri

  • Creighton Diabetes Center

    Omaha, Nebraska

  • Saint Barnabas Medical Center

    Livingston, New Jersey

  • University of Medicine & Dentistry of NJ

    New Brunswick, New Jersey

  • Albany Medical Center

    Albany, New York

  • Schneider Children's Hospital

    New Hyde Park, New York

  • Joslin Diabetes Center

    Syracuse, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • St. Mary Medical Center

    Langhorne, Pennsylvania

  • Sumter Medical Specialists

    Sumter, South Carolina

  • University Diabetes & Endocrine Consultants

    Chattanooga, Tennessee

  • Methodist Healthcare

    Memphis, Tennessee

  • Research Institute of Dallas

    Dallas, Texas

  • Spectra Research Center

    McAllen, Texas

  • Diabetes and Glandular Disease Research

    San Antonio, Texas

  • Endocrine Research Specialists

    Ogden, Utah

  • Pacific Northwest Research Institute

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Alberta Children's Hospital

    Calgary, Alberta, Canada

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.